March 11, 2015
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Actavis launches generic version of Temovate for treatment of dermatoses
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Actavis has announced the launch of a generic version of Temovate cream, according to a company press release.
Temovate (clobetasol cream 0.05%, Fougera Pharmaceuticals) is a high-potency corticosteroid indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, according to the release. IMS health data showed the clobetasol cream had total U.S. brand and generic sales of approximately $185 million for the year ending Jan. 15, 2015, according to the release.
The launch is aimed to help strengthen Actavis’ growing portfolio of topical products.
Reference: www.actavis.com.